For Healthcare Professionals

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With or Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: An Extension Trial to NN1250-3582

clipboard-pencil

About the study

This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this 26 week extension trial is to investigate the long-term safety in terms of comparing NN1250 with insulin glargine plus insulin aspart with or without metformin and with or without pioglitazone in subjects with type 2 diabetes. Subjects who consent to participate in the extension trial will continue to receive the treatment to which they were randomly allocated in the 52 week trial NN1250-3582.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Completion of the 52 week treatment period in NN1250-3582

EXCLUSION CRITERIA

    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply


    Contact the study center to learn if this study is a good match for you.

    Study’s details


    Contition

    Diabetes Mellitus, Type 2

    Age (in years)

    18 - 200

    Phase

    Phase 3

    Participants needed

    819

    Est. Completion Date

    May 2011

    Treatment type

    Interventional


    Sponsor

    Novo Nordisk

    ClinicalTrials.gov identifier

    NCT01193322

    Study number

    NN1250-3667

    Understanding Clinical Trials


    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
    Vector

    Interested?

    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.